Page 12 - Angle Plc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Angle hails Washington University research showing utility of Parsortix system

Scientists successfully used the Parsortix system to harvest disseminated tumour cells, or DTCs, "hibernating" in the bone marrow

ANGLE develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention,...

ANGLE reports encouraging results from Parsortix oesophageal cancer study Oesophageal cancer is a deadly disease with 80% patient mortality at 5 years from diagnosis, partly due to late diagnosis ANGLE PLC (LON:AGL) said that a study at the University Hospital Ghent, Belgium showed its liquid biopsy system Parsortix consistently harvested oesophageal cancer cells in patients suffering from the disease. These are the first published results in this cancer type, said ANGLE, and means the Parsortix system is now validated in 24 cancer types in 28 independent cancer research centres located acro...

About ANGLE plc www.angleplc.com ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLE's cell separation technology is called the Parsortix ®   system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for mu...